Palvella Therapeutics, Inc.
PVLA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001583648
In the last 90 days, Palvella Therapeutics, Inc. insiders filed 0 open-market purchases and 5 sales; 196 institutions reported holding it in 13F filings for Q2 2026, worth $2.15B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Palvella Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 3 insiders, $6.17M in total
- Insiders trading
- 3
- Net value
- −$6.17M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Palvella Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Goin Kathleen | Chief Operating Officer | 0 | Sep 18, 2026 | 12 |
| Jenkins George M | Director | 160,116 | Sep 15, 2026 | 4 |
| Kiritsy Christopher P | Director | 250 | Sep 4, 2026 | 2 |
| Pauls Matthew | Director | – | Jul 1, 2026 | 1 |
| Korenberg Matthew E | CFO, Treasurer | 1,000 | Jun 16, 2026 | 2 |
| Heron Elaine J | Director | 47,812 | Jun 12, 2026 | 2 |
| Davis Todd C | Director | – | Jun 12, 2026 | 1 |
| Doux John | Director | – | Jun 12, 2026 | 2 |
| Wessel Tadd S. | Director | – | Jun 12, 2026 | 1 |
| Martini Jeffrey S | Chief Scientific Officer | – | Feb 9, 2026 | 1 |
| Kaupinen Wes | President and CEO | – | Feb 9, 2026 | 1 |
| Kline Ashley Hartmann | Chief Commercial Officer | – | Feb 9, 2026 | 1 |
| Palvella Therapeutics, Inc. | Chief Scientific Officer | – | Feb 7, 2025 | 0 |
| Biotechnology Value Fund L P | Other: See Explanation of Responses | 38,961 | Dec 17, 2024 | 0 |
| BVF Partners L P | Other: See Explanation of Responses | 38,961 | Dec 17, 2024 | 0 |
| BVF Inc | Other: See Explanation of Responses | 38,961 | Dec 17, 2024 | 0 |
| Biotechnology Value Fund II LP | Other: See Explanation of Responses | 38,961 | Dec 17, 2024 | 0 |
| Lampert Mark N | Other: See Explanation of Responses | 38,961 | Dec 17, 2024 | 0 |
| Biotechnology Value Trading Fund OS LP | Other: See Explanation of Responses | 38,961 | Dec 17, 2024 | 0 |
| BVF Partners OS Ltd. | Other: See Explanation of Responses | 38,961 | Dec 17, 2024 | 0 |
| BVF I GP LLC | Other: See Explanation of Responses | 38,961 | Dec 17, 2024 | 0 |
| BVF II GP LLC | Other: See Explanation of Responses | 38,961 | Dec 17, 2024 | 0 |
| BVF GP Holdings LLC | Other: See Explanation of Responses | 38,961 | Dec 17, 2024 | 0 |
| Dellora Investments LP | Other: no longer 10% owner | – | Dec 16, 2024 | 0 |
| Geraghty James A | Director | 0 | Dec 12, 2024 | 0 |
| ADAR1 Partners, LP | 10% Owner | 15,067Indirect | Aug 12, 2024 | 0 |
| ADAR1 Capital Management, LLC | 10% Owner | 15,067Indirect | Aug 12, 2024 | 0 |
| Sherman Matthew L | Director | – | Jun 23, 2023 | 0 |
| Kiener Peter A | Director | – | Jun 23, 2023 | 0 |
| Richman Michael | Director | – | Jun 23, 2023 | 0 |
| Barbier Ann | Director | – | Jun 23, 2023 | 0 |
| Said Maya R. | Director | – | Jun 23, 2023 | 0 |
| Yoder Stephen S. | Chief Executive Officer | – | Feb 28, 2023 | 0 |
| Bures Thomas | Chief Financial Officer | – | Feb 28, 2023 | 0 |
| Kaufmann Hitto | Chief Scientific Officer | – | Feb 28, 2023 | 0 |
| Olwill Shane | Chief Development Officer | 4,638 | Feb 28, 2023 | 0 |
| Mousa Ahmed | Chief Business Officer | – | Feb 28, 2023 | 0 |
| Demuth Tim | Chief Medical Officer | 6,000 | May 16, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 (view filing)4:05 PM ET | Sep 16 | 2 days | Goin KathleenChief Operating Officer | SSale | −4.30K | $152.24 | −$654.9K | −100.0%0 after | 3 lots10b5-1 |
| Sep 15, 2026 (view filing)9:15 PM ET | Sep 11-15 | 4 days | Jenkins George MDirector | SSale | −27.5K | $151.53 | −$4.17M | −14.7%160.1K after | 9 lots10b5-1 |
| Sep 4, 2026 (view filing)4:05 PM ET | Sep 2 | 2 days | Kiritsy Christopher PDirector | SSale | −313 | $157.00 | −$49.1K | −55.6%250 after | |
| Aug 20, 2026 (view filing)4:05 PM ET | Aug 19 | 1 day | Goin KathleenChief Operating Officer | SSale | −4.30K | $152.21 | −$654.8K | −100.0%0 after | 5 lots10b5-1 |
| Jul 17, 2026 (view filing)4:05 PM ET | Jul 15 | 2 days | Goin KathleenChief Operating Officer | SSale | −4.30K | $149.28 | −$642.2K | −100.0%0 after | 4 lots10b5-1 |
| Jun 22, 2026 (view filing) | Jun 17 | 5 days | Goin KathleenChief Operating Officer | SSale | −4.30K | $110.73 | −$476.4K | −100.0%0 after | 3 lots10b5-1 |
| May 22, 2026 (view filing) | May 20 | 2 days | Goin KathleenChief Operating Officer | SSale | −4.30K | $110.56 | −$475.6K | −100.0%0 after | 3 lots10b5-1 |
| Apr 17, 2026 (view filing) | Apr 15 | 2 days | Goin KathleenChief Operating Officer | SSale | −4.30K | $127.24 | −$547.4K | −100.0%0 after | 5 lots10b5-1 |
| Apr 1, 2026 (view filing) | Mar 30 | 2 days | Jenkins George MDirector | PPurchase | +445 | $112.30 | +$50.0K | +0.2%187.6K after | |
| Mar 20, 2026 (view filing) | Mar 18 | 2 days | Goin KathleenChief Operating Officer | SSale | −4.30K | $117.99 | −$507.6K | −100.0%0 after | 3 lots10b5-1 |
| Mar 2, 2026 (view filing) | Feb 27 | 3 days | Jenkins George MDirector | PPurchase | +4.00K | $125.00 | +$500.0K | +2.2%187.2K after | |
| Mar 2, 2026 (view filing) | Feb 27 | 3 days | Heron Elaine JDirector | PPurchase | +2.40K | $125.00 | +$300.0K | +5.3%47.8K after | |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Goin KathleenChief Operating Officer | SSale | −4.30K | $79.40 | −$341.6K | −100.0%0 after | 2 lots10b5-1 |
| Jan 23, 2026 (view filing) | Jan 21 | 2 days | Goin KathleenChief Operating Officer | SSale | −4.30K | $97.63 | −$420.0K | −100.0%0 after | 2 lots10b5-1 |
| Dec 19, 2025 (view filing) | Dec 17 | 2 days | Goin KathleenChief Operating Officer | SSale | −4.30K | $96.47 | −$415.0K | −100.0%0 after | 10b5-1 |
| Nov 21, 2025 (view filing) | Nov 19 | 2 days | Goin KathleenChief Operating Officer | SSale | −4.30K | $86.23 | −$371.0K | −100.0%0 after | 2 lots10b5-1 |
| Apr 10, 2025 (view filing) | Apr 9 | 1 day | Jenkins George MDirector | PPurchase | +2.50K | $20.13 | +$50.3K | +1.4%183.2K after | |
| Apr 10, 2025 (view filing) | Apr 9 | 1 day | Jenkins George MDirector | PPurchase | +2.49K | $20.27 | +$50.5K | +22.6%13.5K after | |
| Dec 19, 2024 (view filing) | Dec 18 | 1 day | Jenkins George MDirector | PPurchase | +4.00K | $12.93 | +$51.7K | +2.3%180.7K after | |
| Oct 28, 2024 (view filing) | Aug 7 | 82 daysLate | Geraghty James ADirector | PPurchaseSeries F Preferred Stock, par value $0.001 per share | +1 | $1.00 | +$1 | New position1 after | |
| Aug 12, 2024 (view filing)6:48 PM ET | Aug 9-12 | 3 days | ADAR1 Partners, LP and 1 other10% Owner | PPurchase | +6.00K | $15.39 | +$92.3K | +66.2%15.1K after | 3 lots |
| May 30, 2023 (view filing) | May 25 | 5 days | Kiritsy Christopher PDirector | PPurchase | +10.0K | $0.85 | +$8.50K | +100.0%20.0K after | |
| May 16, 2022 (view filing) | May 13 | 3 days | Demuth TimChief Medical Officer | PPurchase | +6.00K | $1.71 | +$10.3K | New position6.00K after | |
| Sep 1, 2021 (view filing) | Aug 30 | 2 days | Olwill ShaneChief Development Officer | SSale | −38.4K | $5.11 | −$196.4K | −89.2%4.64K after | 2 lots |